From the Cynata website:
Cynata's Cymerus™ technology is underpinned by a series of patents (including granted patents and patent applications) licensed from the Wisconsin Alumni Research Foundation (WARF) - an organisation established to commercialise technology invented at the University of Wisconsin-Madison.
In brief, these patents describe a process to generate mesenchymal stem cells (MSCs) under serum-free conditions, using pluripotent stem cells (including iPSCs) as a starting material. To Cynata's knowledge, this is currently the only process proven to be capable of commercially producing clinical grade MSCs from iPSCs. The key patent rights licensed to Cynata do not expire until between 2028 and 2034.
44c thank you, page-16
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.11M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 20.0¢ | $26.24K | 131.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 78722 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 15873 | 1 |
View Market Depth
| Last trade - 15.34pm 16/08/2024 (20 minute delay) ? |
| CYP (ASX) Chart |